Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024 Extended pre-clinical, clinical and IP package…
Bind Research launched to transform disordered proteins into effective drug targets UK’s first not-for-profit Focused Research Organisation supported by Department…